Daily Respiratory Research Analysis
Three high-impact studies advance respiratory science and policy. Hybrid immunity generates durable pan-coronavirus T cell responses across ages, informing next-generation vaccine design. A 200k-person cohort from Shanghai shows post-infection vaccination reduces Omicron reinfection, with stronger protection when timed nearer to exposure; and a large NHANES analysis links PRISm to markedly higher all-cause mortality over ~26 years.
Summary
Three high-impact studies advance respiratory science and policy. Hybrid immunity generates durable pan-coronavirus T cell responses across ages, informing next-generation vaccine design. A 200k-person cohort from Shanghai shows post-infection vaccination reduces Omicron reinfection, with stronger protection when timed nearer to exposure; and a large NHANES analysis links PRISm to markedly higher all-cause mortality over ~26 years.
Research Themes
- Hybrid immunity and pan-coronavirus T-cell responses for vaccine design
- Effectiveness and timing of post-infection COVID-19 booster doses
- Long-term mortality risk associated with PRISm spirometric pattern
Selected Articles
1. Hybrid immunity-based induction of durable pan-endemic-coronavirus immunity in the elderly.
Hybrid immunity (vaccination plus SARS-CoV-2 infection) induces high-frequency, functionally avid pan-endemic-coronavirus reactive T cells across age groups, unlike vaccination alone. These spike-independent T cell responses may offset waning antibodies and immune escape, supporting inclusion of pan-coronavirus T cell epitopes in future vaccines, especially for the elderly.
Impact: Provides mechanistic, cross-age evidence that hybrid immunity yields durable pan-coronavirus T-cell memory, a key consideration for next-generation vaccines resilient to variant escape.
Clinical Implications: While not immediately altering clinical care, the data support vaccine strategies that incorporate conserved, non-spike T cell epitopes to protect older adults despite waning antibodies.
Key Findings
- Hybrid immunity generated high frequencies of pan-human endemic coronavirus (PHEC)-reactive T cells across all age groups.
- Functional TCR avidities were comparable across ages and higher than in vaccination-only individuals.
- Spike-excluding peptide pools elicited robust T-cell responses, suggesting protection beyond spike-targeted immunity.
- Findings argue for inclusion of pan-coronavirus T-cell epitopes in future vaccine designs.
Methodological Strengths
- Use of SARS-CoV-2-specific and pan-coronavirus peptide pools including spike-independent epitopes
- Functional assessment of T-cell responses and TCR avidity across age groups
Limitations
- Cross-sectional immunologic assessment without clinical outcome endpoints
- Sample size and cohort composition details are not specified in the abstract
Future Directions: Prospective studies linking pan-coronavirus T-cell metrics to clinical protection and trials testing vaccines enriched for conserved T-cell epitopes in older adults.
Repeated vaccinations and infections have led to diverse states of hybrid immunity against SARS-CoV-2 in the global population. However, age and comorbidities can compromise protection against severe disease, and antibody-mediated immunity is undercut by viral immune escape mutations. Whether and to what extent durable T cell responses compensate for reduced humoral immunity, particularly in the elderly, have not been investigated. Here, we utilize SARS-CoV-2-specific and pan-coronavirus-derived peptide pools, including or excluding spike glycoprotein-derived epitopes, to measure vaccination and infection induced pan-human endemic coronavirus (PHEC)-directed T cell immunity. In contrast to vaccinated individuals, hybrid immunity induced by vaccination and SARS-CoV-2 infection comprises high frequencies of PHEC-reactive T cells with comparable frequencies and functional TCR avidities across all age groups. With waning humoral immunity and vulnerability to escape mutations, PHEC-reactive T cells may provide critical protection. Our findings underscore the importance of incorporating pan-coronavirus T cell epitopes in future vaccine strategies.
2. Protection afforded by post-infection SARS-CoV-2 vaccine doses: A cohort study in Shanghai.
In a population-based cohort of 199,312 previously infected and vaccinated individuals, a post-infection vaccine dose reduced Omicron reinfection risk (aHR 0.82). Protection was stronger when vaccination occurred closer to exposure (aHR 0.51 within 30 days vs 0.67 within 90 days) and generally beneficial across vaccine types and prior dose histories.
Impact: Large-scale real-world evidence quantifies added protection from post-infection boosting and highlights timing effects, directly informing booster policy in hybrid immunity populations.
Clinical Implications: Supports offering booster doses to previously infected individuals, with consideration for timing (closer to anticipated exposure waves yields stronger protection) and broad applicability across vaccine platforms.
Key Findings
- Post-infection vaccination reduced reinfection risk overall (aHR 0.82; 95% CI 0.79-0.85).
- Protection was stronger when the booster was given within 30 days before the subsequent wave (aHR 0.51) versus within 90 days (aHR 0.67).
- Benefit observed across vaccine types; effect varied with prior dose history (attenuated after three prior doses: HR 0.96).
Methodological Strengths
- Very large, population-based cohort with linked infection and vaccination records
- Adjusted Cox models with timing and prior-dose stratified analyses
Limitations
- Retrospective design with potential residual confounding and testing/ascertainment bias
- Generalizability may vary across regions, variants, and testing policies
Future Directions: Prospective evaluations of booster timing strategies, variant-specific effectiveness, and durability; integration with severe outcome metrics and cost-effectiveness analyses.
BACKGROUND: In many settings, a large fraction of the population has both been vaccinated against and infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, quantifying the protection provided by post-infection vaccination has become critical for policy. We aimed to estimate the protective effect against SARS-CoV-2 reinfection of an additional vaccine dose after an initial Omicron variant infection. METHODS: We report a retrospective, population-based cohort study performed in Shanghai, China, using electronic databases with information on SARS-CoV-2 infections and vaccination history. We compared reinfection incidence by post-infection vaccination status in individuals initially infected during the April-May 2022 Omicron variant surge in Shanghai and who had been vaccinated before that period. Cox models were fit to estimate adjusted hazard ratios (aHRs). RESULTS: 275,896 individuals were diagnosed with real-time polymerase chain reaction-confirmed SARS-CoV-2 infection in April-May 2022; 199,312/275,896 were included in analyses on the effect of a post-infection vaccine dose. Post-infection vaccination provided protection against reinfection (aHR 0.82; 95% confidence interval 0.79-0.85). For patients who had received one, two, or three vaccine doses before their first infection, hazard ratios for the post-infection vaccination effect were 0.84 (0.76-0.93), 0.87 (0.83-0.90), and 0.96 (0.74-1.23), respectively. Post-infection vaccination within 30 and 90 days before the second Omicron wave provided different degrees of protection (in aHR): 0.51 (0.44-0.58) and 0.67 (0.61-0.74), respectively. Moreover, for all vaccine types, but to different extents, a post-infection dose given to individuals who were fully vaccinated before first infection was protective. CONCLUSIONS: In previously vaccinated and infected individuals, an additional vaccine dose provided protection against Omicron variant reinfection. These observations will inform future policy decisions on COVID-19 vaccination in China and other countries. FUNDING: This study was funded the Key Discipline Program of Pudong New Area Health System (PWZxk2022-25), the Development and Application of Intelligent Epidemic Surveillance and AI Analysis System (21002411400), the Shanghai Public Health System Construction (GWVI-11.2-XD08), the Shanghai Health Commission Key Disciplines (GWVI-11.1-02), the Shanghai Health Commission Clinical Research Program (20214Y0020), the Shanghai Natural Science Foundation (22ZR1414600), and the Shanghai Young Health Talents Program (2022YQ076).
3. Risk of All-Cause Mortality in US Adults With Preserved Ratio Impaired Spirometry: An Observational Study.
In a nationally representative cohort of 24,691 adults with ~26 years of follow-up, PRISm was associated with substantially higher all-cause mortality versus normal spirometry (adjusted HR 1.69). The association was consistent across sensitivity and subgroup analyses.
Impact: Establishes PRISm as a high-risk spirometric phenotype in the general population over decades, underscoring the need for recognition, monitoring, and targeted interventions.
Clinical Implications: Clinicians should identify PRISm on spirometry, counsel on risk factor modification, and consider closer surveillance for cardiopulmonary comorbidities and mortality risk.
Key Findings
- Among 24,691 adults (median follow-up 25.7 years), PRISm was linked to higher all-cause mortality (adjusted HR 1.69; 95% CI 1.54–1.86).
- Unadjusted mortality risk was markedly elevated (HR 2.47), and robustness was confirmed in sensitivity and subgroup analyses.
- Findings support PRISm as a clinically meaningful spirometric phenotype beyond normal vs obstructed categories.
Methodological Strengths
- Large, nationally representative NHANES cohorts with very long follow-up
- Adjusted hazard models with sensitivity and subgroup analyses
Limitations
- PRISm defined on pre-bronchodilator spirometry; potential misclassification
- Observational design with residual confounding; cause-specific mortality details not provided in abstract
Future Directions: Elucidate mechanisms and test targeted interventions (e.g., pulmonary rehab, cardio-metabolic risk management) to modify outcomes in PRISm.
BACKGROUND: Preserved ratio impaired spirometry (PRISm) is defined as forced expiratory volume in one second (FEV METHODS: We used data from the National Health and Nutrition Examination Survey III and 2007-2012. Participants aged 20-79 years at baseline and who underwent spirometry were included. Normal spirometry was defined as a prebronchodilator FEV RESULTS: Overall, 24,691 participants were included, with a median follow-up time of 25.7 years. Of these, 19,969 had normal spirometry and 1,452 had PRISm. PRISm was associated with a high all-cause mortality risk (unadjusted hazard ratio [HR]=2.47, 95% confidence interval [CI]: 2.25-2.71, P<0.001; adjusted HR=1.69, 95% CI: 1.54-1.86, P<0.001) compared with normal spirometry. Sensitivity analyses and subgroup analyses showed a similar increased all-cause mortality risk in PRISm. CONCLUSION: Our finding revealed that PRISm was significantly associated with increased risk of all-cause mortality in the general population compared with normal spirometry. Further research is needed to explore the intervention effect of PRISm.